Table 2.
Stratified analysis of pooled HRs for digestive cancer patients with lower transthyretin.
| Subgroup factor | Divided standard | No. of studies | Pooled HR (95% CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|---|
| I 2 (%) | P het | |||||
| Cancer type | GI tract cancer | 5 | 1.92 (1.11-2.73) | <0.001 | 74.1 | 0.004 |
| Non-GI tract cancer | 6 | 1.62 (1.29-1.96) | <0.001 | 28.2 | 0.223 | |
|
| ||||||
| Cut-off value | <180 mg/L | 5 | 1.47 (1.27-1.68) | <0.001 | 0.0 | 0.451 |
| ≥180 mg/L | 6 | 1.98 (1.26-2.69) | <0.001 | 76.4 | 0.001 | |
|
| ||||||
| Treatment | No surgery | 2 | 1.62 (0.29-2.96) | NS | 74.6 | 0.047 |
| With surgery | 9 | 1.78 (1.45-2.12) | <0.001 | 33.4 | 0.150 | |
|
| ||||||
| Analysis type | UVA | 3 | 2.35 (1.68-3.02) | <0.001 | 0.0 | 0.607 |
| MVA | 8 | 1.53 (1.21-1.85) | <0.001 | 58.8 | 0.018 | |
|
| ||||||
| Follow-up | <5 years | 4 | 1.46 (0.97-1.95) | NS | 61.3 | 0.052 |
| ≥5 years | 7 | 1.98 (1.46-2.49) | <0.001 | 43.9 | 0.098 | |
|
| ||||||
| Clinical stage | Nonmetastatic | 2 | 1.45 (1.22-1.68) | <0.001 | 0.0 | 0.503 |
| Metastatic | 2 | 1.62 (0.29-2.96) | NS | 74.6 | 0.047 | |
| Mixed | 7 | 1.97 (1.54-2.39) | <0.001 | 23.1 | 0.253 | |
GI: gastrointestinal; HR: hazard ratio; 95% CI: 95% confidence interval; UVA: univariate analysis; MVA: multivariate analysis; NS: not significant.